Needham Reiterates Buy on Clearside Biomedical, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has reiterated a Buy rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a $4 price target.
August 13, 2024 | 9:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst Serge Belanger has reiterated a Buy rating on Clearside Biomedical and maintained a $4 price target.
The reiteration of a Buy rating and the maintenance of a $4 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100